Jnk Inhibitors For Neurodegenerative Diseases is a treatment approach for neurodegenerative . This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
The c-Jun N-terminal kinase (JNK) signaling pathway is a key mediator of neuronal apoptosis, neuroinflammation, and protein aggregation in neurodegenerative . JNK inhibitors represent a promising therapeutic strategy for Alzheimer's disease, Parkinson's disease, and other disorders. [1]
JNK (c-Jun N-terminal kinase) is a member of the mitogen-activated protein kinase (MAPK) family that plays critical roles in cellular stress responses. In the brain, JNK pathway activation contributes to neuronal death through multiple including apoptosis, neuroinflammation, and acceleration of protein aggregation pathologies. The three JNK isoforms (JNK1, JNK2, and JNK3) have distinct expression patterns, with JNK3 being neuron-specific and thus the primary therapeutic target for neurodegenerative . [2]
The rationale for JNK inhibition in neurodegeneration stems from extensive preclinical evidence demonstrating that JNK activation drives key pathological processes including: (1) mitochondrial dysfunction and apoptotic neuronal death; (2) enhanced tau hyperphosphorylation and neurofibrillary tangle formation; (3) alpha-synuclein aggregation and toxicity; (4) neuroinflammation through glial activation and cytokine production; and (5) excitotoxicity. Despite strong biological rationale, clinical development of JNK inhibitors has faced challenges related to blood-brain barrier penetration, isoform selectivity, and safety concerns. [3]
JNK belongs to the MAPK family and is activated by cellular stress, including: [4]
Three JNK isoforms exist: [6]
JNK3 is the isoform most implicated in neurodegeneration due to its neuronal specificity. [7]
| Compound | Company | Stage | Notes | [8]
|----------|---------|-------|-------|
| SP600125 | Research compound | Preclinical | Broad JNK inhibitor, first-generation |
| JNK-IN-8 | Research compound | Preclinical | Selective JNK3 inhibitor |
| CC-90009 | Celgene/BMS | Clinical | GSPT1 molecular glue, indirect JNK modulation |
| IQ-1S | Research compound | Preclinical | Selective JNK1/2 inhibitor |
The study of Jnk Inhibitors For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kim YA, Lim SY, Rhee SH, et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. 2006. ↩︎
Mandel SA, Avramovich-Tirosh Y, Reznichenko L, et al. Modulating tau pathologies by green tea (-)-epigallocatechin-3-gallate. 2008. ↩︎
Zhu X, Lee HG, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: an update. 2007. ↩︎
Yarza R, Vela S, Solas M, Ramirez MJ. c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease. 2016. ↩︎
Lin E, Cavanaugh JE, Leak RK, Perez RG, Zenko RP. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. 2008. ↩︎
Wu Y, Deng Y, Zhang S, et al. Alpha-synuclein aggregation and dopaminergic neuronal death in a mouse model of Parkinson's disease. 2011. ↩︎
Kuan WL, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's therapy. 2010. ↩︎
Ferrer I, Goutan E, Marín C, Rey MJ, Pelegri C. Brain-derived neurotrophic factor in Huntington disease. 2000. ↩︎